Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
MediciNova, Inc. (NASDAQ: MNOV) announced the publication of research demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) model. The study, published in Molecular Cancer Research, revealed that MN-166 significantly reduced UM cell migration and metastasis in mice, emphasizing its potential as an adjuvant therapy for UM patients. The research identified macrophage migration inhibitory factor (MIF) as a key target, suggesting that MIF inhibition through MN-166 could address critical needs in metastatic cancer treatment.
MediciNova, a biopharmaceutical company traded as MNOV, announced the completion of patient enrollment in a Phase 2 clinical trial for MN-166 (ibudilast) targeting hospitalized COVID-19 patients at risk for acute respiratory distress syndrome (ARDS). The trial, which involved administering MN-166 or a placebo to subjects over 7 days, aims to assess its efficacy in preventing respiratory failure. Top-line results will be reported following data cleaning. MN-166 is also in late-stage development for other conditions like ALS and multiple sclerosis.
MediciNova, Inc. announced the FDA's completion of its review for a Phase 2 trial of MN-001 (tipelukast), aimed at treating non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2DM), and hypertriglyceridemia. This trial follows promising results from a prior study where MN-001 successfully reduced serum triglycerides and improved lipid profiles, particularly in T2DM patients. The upcoming study will evaluate liver fat content and serum lipids, with full funding from MediciNova.
MediciNova has published a secondary analysis of a Phase 2 trial for MN-166 (ibudilast) in treating alcohol use disorder (AUD) in Alcoholism: Clinical and Experimental Research. The study involved 52 participants and revealed that MN-166 significantly reduced heavy drinking rates and cravings. The analysis showed it didn't alter stimulation/sedation levels but moderated daily stimulation effects on alcohol consumption. With an estimated 14.5 million people affected by AUD in the U.S., the study highlights a critical need for better treatment options.
MediciNova, a biopharmaceutical company traded as NASDAQ:MNOV, announced a Notice of Allowance from the Korean Intellectual Property Office for patents covering MN-001 (tipelukast) and its metabolite MN-002, aimed at treating advanced nonalcoholic steatohepatitis (NASH). The patent is expected to expire no earlier than May 2035 and covers multiple aspects of treatment, including dosing forms and frequencies. Positive results from a prior Phase 2 clinical trial of MN-001 with NASH patients alongside FDA's Fast Track designation further highlight its potential.
MediciNova, Inc. (NASDAQ: MNOV) has announced that Geoffrey O'Brien, the Vice President and Executive Officer, will present at the 2022 Virtual Growth Conference, scheduled for March 28-30, 2022. MediciNova is a clinical-stage biopharmaceutical company with a focus on developing novel therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its lead asset, MN-166 (ibudilast), is in Phase 3 trials for ALS and DCM, while MN-001 (tipelukast) is preparing for a Phase 2 trial in NASH. MediciNova has a strong pipeline with 11 programs currently in clinical development.
MediciNova, Inc. announced that MN-166 (ibudilast) is highlighted in the Global Spine Journal as a potential treatment for degenerative cervical myelopathy (DCM). The publication reviews therapies that support neuroprotection, neuroregeneration, and neuromodulation. MN-166 is noted for its anti-inflammatory and neuroprotective effects, making it the only drug currently in Phase 3 trials for DCM. Chief Medical Officer Kazuko Matsuda expressed optimism regarding MN-166's potential to aid patients with DCM, a condition that often leads to lifelong disability.
MediciNova (NASDAQ: MNOV) announced that MN-166 (ibudilast) is recognized as a promising treatment for alcohol use disorder (AUD) in a journal publication. The article, co-authored with Dr. Lara Ray, outlines that MN-166 is effective in reducing alcohol intake and cravings, improving mood, and mitigating the effects of alcohol. With 14.5 million individuals in the U.S. suffering from AUD, and only a small percentage receiving treatment, MN-166's potential could address this significant medical need. The drug is in late-stage development for multiple conditions.
MediciNova, a biopharmaceutical company, announced it received a new patent from the Korean Intellectual Property Office for MN-001 (tipelukast) aimed at treating hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. The patent is expected to expire no earlier than July 2034 and covers various dosages and administration forms. The company notes promising results from its Phase 2 trial with MN-001, showing a significant reduction in serum triglycerides. MediciNova continues to develop innovative therapies for various diseases.
MediciNova, Inc. (NASDAQ: MNOV) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent concerning MN-001 (tipelukast) and its metabolite MN-002, which target hepatic ballooning. This patent is anticipated to be granted by January 2035 and covers various oral administration forms. The Chief Medical Officer highlighted MN-001's efficacy in improving NASH pathology in animal models. MediciNova is focused on developing therapies for inflammatory and fibrotic diseases, currently advancing multiple clinical programs, including MN-166 for ALS.